<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Manzardo, Christian</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efavirenz-Based Therapy Effective in Highly Suppressed HIV-1–Infected Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">In the ADVANZ-3 trial, among patients with advanced HIV-1, 96 weeks of daily combination treatment with efavirenz plus tenofovir/emtricitabine is as effective in increasing CD4+ T-cell levels as daily combination treatment using atazanavir/ritonavir plus tenofovir/emtricitabine or lopinavir/ritonavir plus tenofovir/emtricitabine. Similar improvements are also seen for inflammation, coagulation, and bacterial translocation markers.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>